Effectiveness of Combining Antiobesity Medication With an Employer-Based Weight Management Program for Treatment of Obesity: A Randomized Clinical Trial.

Pantalone KM, Smolarz BG, Ramasamy A, Baz Hecht M, Harty BJ, Rogen B, Griebeler ML, Borukh E, Young JB, Burguera B

JAMA network open1 Jul 2021Cited by 24 (Europe PMC)

PMID34255049PMCIDPMC8278271DOI10.1001/jamanetworkopen.2021.16595PepBankPUB-34255049

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, a program plus one of five anti-obesity medications (including liraglutide 3.0 mg) gave greater weight loss at month 12 than the program alone.
In plain wordsIn adults with obesity, a workplace program plus one of five weight loss drugs led to more weight loss than the program alone.
Peptide
Liraglutide
Outcome
DecreasePercentage change in body weight at month 12
Study
n = 200
Comparator
Weight management program alone
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
Weight change
−7.7%
program plus medication
Weight change
−4.2%
program alone
Treatment difference
−3.5%
95% CI -5.5 to -1.5
Source sentences
Summary
For the primary intention-to-treat estimand, the estimated mean (SE) weight loss was -7.7% (0.7%) for the WMP+Rx group vs -4.2% (0.7%) for the WMP group, with an estimated treatment difference of -3.5% (95% CI, -5.5% to -1.5%) (P < .001).
2 context sentences(design, population, supporting numbers)
Summary · context
In total, 200 participants were randomized 1:1, 100 participants to WMP combined with an AOM (WMP+Rx), and 100 participants to WMP alone.
Summary · context
Participants in the WMP+Rx group initiated treatment with 1 of 5 US Food and Drug Administration-approved medications for chronic weight management (orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide, 3.0 mg) according to standard clinical practice.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3425504901
02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, more participants reached at least 5% weight loss with a program plus one of five anti-obesity medications (including liraglutide) than with the program alone.
In plain wordsIn obesity, more people lost 5% of weight or more with a program plus a weight loss drug than with the program alone.
Peptide
Liraglutide
Outcome
IncreaseAt least 5% weight loss
Study
n = 200
Comparator
Weight management program alone
Outcome group
Body weight · Metabolic and weight
Measurements
Participants with >=5% weight loss
62.5%
program plus medication
Participants with >=5% weight loss
44.8%
program alone
Source sentences
Summary
The estimated percentage of participants achieving at least 5% weight loss was 62.5% for WMP+Rx vs 44.8% for WMP (P = .02).
2 context sentences(design, population, supporting numbers)
Summary · context
In total, 200 participants were randomized 1:1, 100 participants to WMP combined with an AOM (WMP+Rx), and 100 participants to WMP alone.
Summary · context
Participants in the WMP+Rx group initiated treatment with 1 of 5 US Food and Drug Administration-approved medications for chronic weight management (orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide, 3.0 mg) according to standard clinical practice.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3425504902
03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, attendance at shared medical appointments was higher with a program plus one of five anti-obesity medications (including liraglutide) than with the program alone.
In plain wordsIn adults with obesity, people given a weight loss drug along with the workplace program attended more appointments than those in the program alone.
Peptide
Liraglutide
Outcome
IncreaseAttendance at shared medical appointments
Study
n = 200
Comparator
Weight management program alone
Outcome group
Exercise and physical function · Whole body
Source sentences
Summary
The rate of attendance at shared medical appointments was higher for the WMP+Rx group than for the WMP group.
2 context sentences(design, population, supporting numbers)
Summary · context
In total, 200 participants were randomized 1:1, 100 participants to WMP combined with an AOM (WMP+Rx), and 100 participants to WMP alone.
Summary · context
Participants in the WMP+Rx group initiated treatment with 1 of 5 US Food and Drug Administration-approved medications for chronic weight management (orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide, 3.0 mg) according to standard clinical practice.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3425504903
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, a program plus one of five anti-obesity medications (including liraglutide) caused no meaningful differences in work productivity or limitation compared with the program alone.
In plain wordsIn adults with obesity, adding a weight loss drug to the workplace program made no meaningful difference to work productivity compared with the program alone.
Peptide
Liraglutide
Outcome
No significant changeWork productivity and limitation measures
Study
n = 200
Comparator
Weight management program alone
Outcome group
Exercise and physical function · Whole body
Source sentences
Summary
No meaningful differences in patient-reported work productivity or limitation measures were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
In total, 200 participants were randomized 1:1, 100 participants to WMP combined with an AOM (WMP+Rx), and 100 participants to WMP alone.
Summary · context
Participants in the WMP+Rx group initiated treatment with 1 of 5 US Food and Drug Administration-approved medications for chronic weight management (orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide, 3.0 mg) according to standard clinical practice.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3425504904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT03799198

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity

Novo Nordisk A/Sn = 2007 Jan 2019 to 22 May 2020

Obesity

Trial page ClinicalTrials.govUpdated 14 Nov 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.